Drug Profile
Research programme: anti-infectives - Merck & Co/Novartis
Alternative Names: Anti-infectives research programme - ArQule/NovartisLatest Information Update: 20 Jan 2020
Price :
$50
*
At a glance
- Originator ArQule; Novartis
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections; Viral infections
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 03 Dec 2003 Preclinical trials in Bacterial infections in USA (unspecified route)
- 03 Dec 2003 Preclinical trials in Viral infections in USA (unspecified route)